What are the recommended acyclovir dosing regimens for herpes simplex infections (primary genital, recurrent genital, labial, encephalitis, neonatal, and pediatric cases) and how should dosing be adjusted in renal impairment?

Acyclovir Dosing for Herpes Simplex Infections

For genital herpes, use acyclovir 400 mg orally three times daily for 7-10 days for first episodes, and for recurrent episodes use 400 mg three times daily for 5 days when started early in the prodrome. 1

Primary Genital Herpes (First Clinical Episode)

Recommended oral regimens for first-episode genital herpes:

• Acyclovir 400 mg orally three times daily for 7-10 days 1
• Alternative: Acyclovir 200 mg orally five times daily for 7-10 days 1
• Treatment may be extended if healing is incomplete after 10 days 1

The 1998 CDC guidelines represent an evolution from earlier recommendations, offering more convenient dosing schedules while maintaining efficacy. 1 The three-times-daily regimen improves adherence compared to the five-times-daily schedule. 1

For first-episode herpes proctitis specifically:

• Higher doses are used: Acyclovir 400 mg orally five times daily for 10 days 1

Recurrent Genital Herpes

Episodic treatment (patient-initiated at first sign of prodrome or within 1 day of lesion onset):

• Acyclovir 400 mg orally three times daily for 5 days 1
• Alternative: Acyclovir 200 mg orally five times daily for 5 days 1
• Alternative: Acyclovir 800 mg orally twice daily for 5 days 1

Early initiation is critical—treatment must begin during prodrome or within 1 day of lesion onset to achieve benefit. 1 Patients should be provided with medication or a prescription in advance to enable immediate self-treatment. 1

Suppressive Therapy for Frequent Recurrences

Daily suppressive therapy (for patients with ≥6 recurrences per year):

• Acyclovir 400 mg orally twice daily 1
• Alternative: Acyclovir 200 mg orally 3-5 times daily (to identify lowest effective dose) 1

Suppressive therapy reduces recurrence frequency by ≥75% in patients with frequent recurrences. 1 Safety and efficacy have been documented for up to 5-6 years of continuous use. 1 After 1 year of continuous suppressive therapy, discontinuation should be discussed to reassess recurrence rate, as frequency often decreases over time. 1

Important caveat: Suppressive therapy reduces but does not eliminate asymptomatic viral shedding, so transmission risk remains. 1

Herpes Labialis (Oral Herpes)

For recurrent herpes simplex labialis:

• Acyclovir 400 mg orally five times daily for 5 days 2
• Treatment must start within 1 hour of first sign or symptom for optimal benefit 2

In clinical trials, oral acyclovir reduced pain duration by 36% and healing time by 27% when started during prodrome or erythema stage. 2 However, the benefit is limited if treatment is delayed beyond the early stages. 2

Severe Disease Requiring Hospitalization

For severe HSV disease with complications (disseminated infection, pneumonitis, hepatitis, or CNS involvement):

• Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 1, 3

IV therapy is indicated for patients requiring hospitalization due to severe disease or complications. 1

Herpes Simplex Encephalitis

For HSV encephalitis in adults and adolescents (≥12 years):

• Acyclovir 10 mg/kg IV every 8 hours for 14-21 days 1, 3

For HSV encephalitis in children (3 months to 12 years):

• Acyclovir 20 mg/kg IV every 8 hours for 10 days 1, 3

Higher doses in pediatric patients (20 mg/kg) have decreased mortality to 5% in neonates with improved neurologic outcomes. 1 Predictors of poor outcome include age >30 years, Glasgow coma score <6, and delay >4 days before starting therapy. 1 A repeat CSF HSV DNA PCR should be performed at days 19-21 of therapy; do not stop acyclovir until repeat CSF PCR is negative. 1

Critical point: There is ongoing debate about optimal pediatric dosing. The FDA-approved dose is 20 mg/kg every 8 hours (60 mg/kg/day), but some experts recommend lower doses to minimize nephrotoxicity risk. 4, 5 One retrospective study found no significant difference in renal injury between standard-dose (30 mg/kg/day) and high-dose (60 mg/kg/day) acyclovir in children. 4

Neonatal Herpes Simplex Infections

For neonatal HSV infections (birth to 3 months):

• Acyclovir 10 mg/kg IV every 8 hours for 10 days 3
• For CNS disease: Acyclovir 20 mg/kg IV every 8 hours for 21 days 1

Higher doses (15-20 mg/kg) have been used in neonates, with 20 mg/kg showing improved outcomes. 1, 3 For neonatal CNS disease, repeat CSF HSV DNA PCR at days 19-21; continue therapy until negative. 1

Important consideration: The risk of acyclovir-associated nephrotoxicity is actually lower in neonates compared to older children, despite initial FDA concerns. 5

Pediatric Dosing (Non-CNS Infections)

For mucosal/cutaneous HSV in immunocompromised children (<12 years):

• Acyclovir 10 mg/kg IV every 8 hours for 7 days 3

For moderate to severe gingivostomatitis:

• Acyclovir 5-10 mg/kg IV every 8 hours until lesions regress, then switch to oral 1
• Oral: Acyclovir 20 mg/kg (max 400 mg/dose) three times daily for 5-10 days 1

For genital herpes in children <45 kg:

• Acyclovir 20 mg/kg (max 400 mg/dose) orally three times daily for 5-14 days 1

Renal Dose Adjustments

Dosing adjustments for renal impairment (based on creatinine clearance): 3

• CrCl >50 mL/min: 100% of dose every 8 hours
• CrCl 25-50 mL/min: 100% of dose every 12 hours
• CrCl 10-25 mL/min: 100% of dose every 24 hours
• CrCl 0-10 mL/min: 50% of dose every 24 hours

For hemodialysis patients:

• Administer an additional dose after each dialysis session (mean half-life during hemodialysis is ~5 hours with 60% decrease in plasma concentrations) 3

For peritoneal dialysis:

• No supplemental dose needed after adjusting the dosing interval 3

Dosing in Obese Patients

For obese patients:

• Dose using Ideal Body Weight (IBW) for standard dosing 3
• However, recent evidence suggests this may result in subtherapeutic concentrations 6
• Consider using adjusted body weight in obese patients with normal renal function 6
• In patients with augmented renal clearance, may use up to maximum recommended doses 6

Special Populations

Geriatric patients:

• Acyclovir plasma concentrations are higher due to age-related renal function changes 3
• Dosage reduction required in geriatric patients with underlying renal impairment 3

Immunocompromised patients:

• May require more aggressive therapy and longer treatment courses 1
• Higher risk of acyclovir-resistant strains, which may require alternative agents (foscarnet 40 mg/kg IV three times daily or 60 mg/kg twice daily) 1

Critical Safety Considerations

Nephrotoxicity prevention:

• NEVER administer as rapid or bolus IV injection—must infuse over 1 hour 3
• Ensure adequate hydration during IV administration 3
• Precipitation of acyclovir crystals in renal tubules can occur if maximum solubility (2.5 mg/mL) is exceeded 3
• Risk factors for nephrotoxicity include: concomitant nephrotoxic drugs, pre-existing renal disease, dehydration, rapid administration, and doses >1500 mg/m² 3, 5

Neurotoxicity:

• Approximately 1% of patients develop encephalopathic changes (lethargy, tremors, confusion, hallucinations, seizures, coma) 3
• Use with caution in patients with underlying neurologic abnormalities, serious renal/hepatic/electrolyte abnormalities, or significant hypoxia 3

IV preparation and administration:

• Reconstitute to 50 mg/mL; dilute for infusion to ≤7 mg/mL 3
• Higher concentrations (e.g., 10 mg/mL) may cause phlebitis or inflammation upon extravasation 3
• Do NOT use bacteriostatic water containing benzyl alcohol or parabens 3
• Use reconstituted solution within 12 hours; diluted solution within 24 hours 3